Notable Reporting: Eagle Pharmaceuticals Inc Can’t Burn Your Long Portfolio. Has Another Strong Session

Notable Reporting: Eagle Pharmaceuticals Inc Can't Burn Your Long Portfolio. Has Another Strong Session

The stock of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) is a huge mover today! About 222,683 shares traded hands. Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has risen 12.15% since March 15, 2016 and is uptrending. It has outperformed by 6.66% the S&P500.
The move comes after 5 months positive chart setup for the $1.04 billion company. It was reported on Oct, 18 by Barchart.com. We have $82.98 PT which if reached, will make NASDAQ:EGRX worth $239.20 million more.

Analysts await Eagle Pharmaceuticals Inc (NASDAQ:EGRX) to report earnings on November, 9. They expect $0.84 earnings per share, up 229.23% or $1.49 from last year’s $-0.65 per share. EGRX’s profit will be $12.95 million for 20.08 P/E if the $0.84 EPS becomes a reality. After $0.80 actual earnings per share reported by Eagle Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 5.00% EPS growth.

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Ratings Coverage

Out of 3 analysts covering Eagle Pharma (NASDAQ:EGRX), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Eagle Pharma has been the topic of 5 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating by Mizuho given on Monday, June 20. The rating was maintained by Mizuho with “Buy” on Friday, February 26. The rating was maintained by Piper Jaffray with “Overweight” on Wednesday, July 29. RBC Capital Markets maintained the shares of EGRX in a report on Tuesday, May 10 with “Outperform” rating. The firm earned “Buy” rating on Wednesday, December 9 by Mizuho.

More important recent Eagle Pharmaceuticals Inc (NASDAQ:EGRX) news were published by: Fool.com which released: “Why Eagle Pharmaceuticals, Inc. Skyrocketed 27.8% Today” on June 10, 2016, also Fool.com published article titled: “Why Eagle Pharmaceuticals Inc. Flew 38.5% Higher in August”, Businesswire.com published: “Eagle Pharmaceuticals, Inc. Reports First Quarter 2016 Results; Bendeka …” on May 09, 2016. More interesting news about Eagle Pharmaceuticals Inc (NASDAQ:EGRX) was released by: Businesswire.com and their article: “Eagle Pharmaceuticals Receives Complete Response Letter from FDA on KANGIO …” with publication date: March 18, 2016.

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company has a market cap of $1.04 billion. The Firm focuses on developing and commercializing injectable products in the critical care and oncology areas. It has a 423.45 P/E ratio. The Company’s product portfolio includes EP-1101 ; Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka).

EGRX Company Profile

Eagle Pharmaceuticals, Inc., incorporated on January 2, 2007, is a specialty pharmaceutical company. The Firm focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka). The Firm has over four product candidates in advanced stages of development, and/or under review for approval by the United States Food and Drug Administration (FDA), which include EP-6101 Kangio ready-to-use (RTU) bivalirudin; EP-4104 (dantrolene sodium) (EP-4104) for exertional heat stroke (EHS), and EP-5101 (pemetrexed) (EP-5101). The Company’s near-term product candidate, Kangio is a liquid intravenous form of Angiomax for percutaneous transluminal angioplasty.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment